EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...

By mid-September, the Centers for Disease Control and Prevention reported the Omicron subvariant KP.3.1.1 accounted for most COVID-19 cases. KP.3.1.1 is a member of a group of variants nicknamed ...

(RTTNews) - Pfizer (PFE) and BioNTech SE (BNTX) announced that the CHMP of the European Medicines Agency has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent ...

The XBB.1.5 subvariant — nicknamed ‘Kraken’ — is arguably the most genetically rich and most transmissible SARS-CoV-2 omicron subvariant yet. News Wrap: Russia shells Bakhmut in eastern ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

The winter season ushers in a new globally spreading COVID-19 variant called XEC, a mix of KS.1.1 and KP.3.3, both from the ...

Invivyd Inc. beat a shareholder lawsuit alleging the biopharma company misled shareholders with optimistic projections about the effectiveness of its Covid-19 treatment against the omicron variant.

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.